↓ Skip to main content
What is this page? Embed badge

Gene Therapy for HIV and Chronic Infections

Overview of attention for book
Cover of 'Gene Therapy for HIV and Chronic Infections'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Gene therapies for hepatitis C virus.
  3. Altmetric Badge
    Chapter 2 Recent Advances in Use of Gene Therapy to Treat Hepatitis B Virus Infection
  4. Altmetric Badge
    Chapter 3 U1 interference (U1i) for Antiviral Approaches.
  5. Altmetric Badge
    Chapter 4 Gene Therapy Strategies to Block HIV-1 Replication by RNA Interference.
  6. Altmetric Badge
    Chapter 5 HIV and Ribozymes.
  7. Altmetric Badge
    Chapter 6 Editing CCR5: A Novel Approach to HIV Gene Therapy
  8. Altmetric Badge
    Chapter 7 Synthetic DNA Approach to Cytomegalovirus Vaccine/Immune Therapy
  9. Altmetric Badge
    Chapter 8 Vector-mediated antibody gene transfer for infectious diseases.
  10. Altmetric Badge
    Chapter 9 HIV Latency and the Noncoding RNA Therapeutic Landscape.
  11. Altmetric Badge
    Chapter 10 C Peptides as Entry Inhibitors for Gene Therapy
  12. Altmetric Badge
    Chapter 11 Aptamer-siRNA Chimeras for HIV.
Attention for Chapter 5: HIV and Ribozymes.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
22 Mendeley
citeulike
1 CiteULike
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
HIV and Ribozymes.
Chapter number 5
Book title
Gene Therapy for HIV and Chronic Infections
Published in
Advances in experimental medicine and biology, January 2015
DOI 10.1007/978-1-4939-2432-5_5
Pubmed ID
25757617
Book ISBNs
978-1-4939-2431-8, 978-1-4939-2432-5
Authors

Robert J Scarborough, Anne Gatignol, Robert J. Scarborough

Abstract

Ribozymes are structured RNA molecules that act as catalysts in different biological reactions. From simple genome cleaving activities in satellite RNAs to more complex functions in cellular protein synthesis and gene regulation, ribozymes play important roles in all forms of life. Several naturally existing ribozymes have been modified for use as therapeutics in different conditions, with HIV-1 infection being one of the most studied. This chapter summarizes data from different preclinical and clinical studies conducted to evaluate the potential of ribozymes to be used in HIV-1 therapies. The different ribozyme motifs that have been modified, as well as their target sites and expression strategies, are described. RNA conjugations used to enhance the antiviral effect of ribozymes are also presented and the results from clinical trials conducted to date are summarized. Studies on anti-HIV-1 ribozymes have provided valuable information on the optimal expression strategies and clinical protocols for RNA gene therapy and remain competitive candidates for future therapy.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 18%
Student > Bachelor 3 14%
Researcher 3 14%
Unspecified 2 9%
Professor 1 5%
Other 2 9%
Unknown 7 32%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 27%
Agricultural and Biological Sciences 4 18%
Unspecified 2 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Immunology and Microbiology 1 5%
Other 1 5%
Unknown 7 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2015.
All research outputs
#18,402,666
of 22,794,367 outputs
Outputs from Advances in experimental medicine and biology
#3,311
of 4,949 outputs
Outputs of similar age
#255,771
of 353,053 outputs
Outputs of similar age from Advances in experimental medicine and biology
#163
of 272 outputs
Altmetric has tracked 22,794,367 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,949 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,053 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 272 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.